Example: bankruptcy
Guideline on the Regulation of Therapeutic Products in New ...
Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products (EMEA/ CHMP/SWP/28367/07 Rev.1) ... Guideline on the Regulation of Therapeutic Products in New Zealand provides additional guidance. The terms ‘unapproved medicine’ and ‘lapsed approval’ are synonymous with ...
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Guideline for the notification of serious breaches of ...
www.ema.europa.eu107 undertaken to comply with the Regulation, for example if a substantial modification is required due 108 to a temporary halt in the trial. 109 . 1 EU CT system encompasses the EU CT portal and database. Guideline for the notificatio n of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol EMA/430909/2016 Page 4/13
Guideline on the scientific application and the practical ...
www.ema.europa.euThis guideline addresses the granting and renewal of conditional marketing authorisations, as well as the subsequent granting of marketing authorisations not subject to specific obligations following their completion. 3. Legal basis The legal basis for this guideline is Article 11 of Commission Regulation (EC) No. 507/2006 on the
Guidelines - Europa
www.esma.europa.euDelegated Regulation (EU) No 2017/565; Articles 6, 15 and 16 (6) of Commission Delegated Regulation (EU) No 2017/584; Articles 6, 7, 8 and 9 of Commission Delegated Regulation (EU) No 2017/571; 1 As of 1 January 2022, the reference to Articles 64(4), 65(5) and 66(3) of MiFID II should be read as referring to Articles